Good manufacturing practice and batch release
In one sentence
Good manufacturing practice controls how a product is made, while batch release checks whether a particular lot meets its specified requirements.
The intuition
A recipe, a controlled kitchen and a checked batch answer different questions. A reliable kitchen can consistently make the intended product. It cannot prove that the recipe will treat cancer. Here the “kitchen” includes facilities, materials, trained people, records and qualified equipment.
How it works
Good manufacturing practice (GMP) builds quality into the process. Chemistry, manufacturing and controls (CMC) describes the product, its production and the evidence that supports consistent quality. Applicable requirements depend on the product and development setting; a slogan on a website cannot establish compliance for a particular lot.
Specifications define what the product must be and which limits it must meet. Testing may assess identity, purity, potency and microbiological safety, together with product-specific features. Potency is an assay of relevant biological activity. It is not the same as clinical efficacy.
Release review brings together test results and manufacturing records. A deviation needs investigation and a justified disposition; retesting until a passing number appears does not make the problem disappear. Stability and handling data also matter between manufacture and administration.
Why it matters in cancer
Personalized products can change sequence between patients while depending on a controlled manufacturing platform. A sequence revision, new formulation or changed cell-processing step may affect biology as well as production. Change control documents the revision and the assessment needed for that specific change.
For a messenger RNA construct, a correct sequence file is only one input. For a chimeric antigen receptor (CAR) cell product, receptor expression alone is only one characterization result. Neither is a complete release package.
How it is measured
| Quality question | Illustrative evidence |
|---|---|
| Is it the intended product? | Identity testing and traceable version records |
| Are unwanted materials controlled? | Purity, impurity and process-control results |
| Does it perform a relevant biological task? | Product-specific potency assay |
| Is microbiological risk controlled? | Applicable contamination, sterility and related testing |
| Does quality persist through use? | Stability, transport, container and handling evidence |
This table is a teaching map, not a universal release checklist. The actual tests and acceptance criteria belong to the authorized product specification.
Worked example
A fictional vaccine lot has the correct sequence and acceptable purity. Its potency result fails the approved criterion. Those passing tests do not cancel the failure. The manufacturer and sponsor must investigate and decide under the controlled process; the lesson does not tell them to administer it.
Common confusions
- GMP is a manufacturing framework, not a treatment-benefit claim.
- A certificate of analysis reports named results; it does not answer every quality or clinical question.
- Regulatory authorization, lot release and patient eligibility are separate gates.
- A platform's prior experience does not establish the quality of every future lot.
Related concepts
Sources and scope
Source check: October 9, 2026. This page explains a method or mechanism. Expert and learner review remain pending.
- FDA vaccine CMC guidance.
- FDA CAR T-cell product-development guidance.
- FDA investigational-product CMC overview.